Gefitinib is a revolutionary drug used in the treatment of non-small cell lung cancer (NSCLC). As a targeted therapy, it works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, which plays a crucial role in cancer cell growth and survival. This drug has significantly improved treatment outcomes for patients with EGFR-mutated NSCLC, offering better survival rates and...